SWOT Analysis for Senores Pharmaceuticals Ltd.

Add SWOT widget to your site/app

High DVM Mid and Small Caps (subscription)
Benjamin Graham Value Screen
Price crossing above SMA20 today, and greater than SMA5
Strong Performer, Getting Expensive (DVM)
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Stock passes majority of CANSLIM Investment criteria
Strong Momentum: Price above short, medium and long term moving averages
Consistent high performing stocks over Five Years
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over 1 Year
Companies with high TTM EPS Growth
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
New 52 week high today
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Growth in Net Profit with increasing Profit Margin (QoQ)
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Companies with reducing Debt
Increasing Revenue every Quarter for the past 4 Quarters
Increasing profits every quarter for the past 4 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
RSI indicating price strength
High Volume, High Gain
Top Gainers
High Volume, High Gain
New 52 Week High
Volume Shockers
Stocks near 52 Week High with Significant Volumes
Stocks Outperforming their Industry Price Change in the Quarter

High DVM Mid and Small Caps (subscription)

Benjamin Graham Value Screen

Price crossing above SMA20 today, and greater than SMA5

Strong Performer, Getting Expensive (DVM)

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Companies with 10% increase in share price over three months, with rising net profit growth

Stock passes majority of CANSLIM Investment criteria

Strong Momentum: Price above short, medium and long term moving averages

Consistent high performing stocks over Five Years

Relative Outperformance versus Industry over 1 Month

Relative Outperformance versus Industry over 1 Year

Companies with high TTM EPS Growth

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

New 52 week high today

High Momentum Scores (Technical Scores greater than 50)

Good quarterly growth in the recent results

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Growth in Net Profit with increasing Profit Margin (QoQ)

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Companies with Low Debt

Companies with reducing Debt

Increasing Revenue every Quarter for the past 4 Quarters

Increasing profits every quarter for the past 4 quarters

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

RSI indicating price strength

High Volume, High Gain

Top Gainers

High Volume, High Gain

New 52 Week High

Volume Shockers

Stocks near 52 Week High with Significant Volumes

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects
PE higher than Industry PE
High PE (PE > 40)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Increasing Trend in Non-Core Income

Companies with growing costs YoY for long term projects

PE higher than Industry PE

High PE (PE > 40)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Increasing Trend in Non-Core Income

FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

US FDA Warning Letter

US FDA Warning Letter

Bullish or Bearish Candlestick Strength - Indices
Bullish Engulfing Pattern (Bullish Reversal)
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Bullish or Bearish Candlestick Strength - Indices

Bullish Engulfing Pattern (Bullish Reversal)

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Senores Pharmaceuticals Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Senores Pharmaceuticals Ltd. has 38 Strengths, 8 Weaknesses, 2 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential